PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine).
On July 10, 2008, the Company announced that the EMEA had granted marketing authorization for ranolazine in all 27 European Union (EU) member states under the brand name Latixa.
"Securing approval for the Ranexa brand name in Europe provides important brand synergy in the world's two largest cardiovascular markets, the U.S. and the EU," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.
Ranexa is approved for use in Europe as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. The product is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily.
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.
CV Therapeutics' approved products in the United States include
Ranexa(R) (ranolazine extended-release tablets), indicated for the
treatment of chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and Lexiscan(TM) (regadenoson)
injection for use as a pharmacologic stress agent in radionuclide
myocardial perfusion imaging in patients unabl
|SOURCE CV Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved